CN1907315A - Orthopaedics disease treating and preventing medicinal composition - Google Patents
Orthopaedics disease treating and preventing medicinal composition Download PDFInfo
- Publication number
- CN1907315A CN1907315A CN 200510088791 CN200510088791A CN1907315A CN 1907315 A CN1907315 A CN 1907315A CN 200510088791 CN200510088791 CN 200510088791 CN 200510088791 A CN200510088791 A CN 200510088791A CN 1907315 A CN1907315 A CN 1907315A
- Authority
- CN
- China
- Prior art keywords
- extract
- pharmaceutical composition
- herba epimedii
- weight ratio
- radix dipsaci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for the effective prevention and treatment of orthopaedic diseases, which is prepared from barren wort extract and dipsacus root extract, which have good synergic action for the prevention and treatment of orthopaedic diseases.
Description
Technical field
The present invention relates to the pharmaceutical composition of a kind of prevention and treatment osteoporosis, specifically the pharmaceutical composition of Herba Epimedii and Radix Dipsaci extract composition.
Background technology
Orthopaedic disease be one worldwide, more and more cause the health problem that people pay attention to.For example, about 200,000,000 people in the whole world suffer from osteoporosis at present, and its sickness rate has leapt to commonly encountered diseases, frequently-occurring disease the 7th.Current research shows that in fact the osteoporosis in that China is considered to the peculiar disease of old people always just exists in the Childhood.Along with aged tendency of population becomes clear day by day, as the degenerative disease of person in middle and old age's pilosity--osteoporosis and complication thereof have become a social health problem and have enjoyed geriatrist's concern, and caused social great attention.Safe and effective radical cure method is not medically also arranged at present, help loose skeleton to restore to the original state.The orthopaedics aspect also has the sickness rate of arthritis, hyperosteogeny diseases also more and more higher, has had a strong impact on the raising of people's quality of life.Therefore, a kind of medicine that can effectively prevent and treat orthopaedic disease of exploitation has important medical and social meaning.
Herba Epimedii is the leaf of Berberidaceae barrenwort Herba Epimedii.Compendium of Material Medica is put down in writing it and is had effects such as " beneficial vital essence, hard muscles and bones are mended the waist knee joint, heart tonifying power "; The action range of Herba Epimedii, as to cardiovascular system, central nervous system, blood system, immune system, antiinflammatory, osteoporosis, defying age, antitumor etc. all with the effect.Herba Epimedii is traditional kidney invigorating and YANG supporting Chinese medicine, all contains Herba Epimedii in the Chinese medicine in the prescription of many treatment osteoporosis.Modern pharmacology studies have shown that the main chemical compositions of Herba Epimedii is flavone and polysaccharide, the effective site of a large amount of research surface barrenwort for treating osteoporosis is flavone (Chinese natural drug, 2004,7,2 (4), 235-239), it can promote osteoblastic proliferation and (or) strengthen its mineralization ability, effectively preventing osteoporosis.
The Radix Dipsaci beginning is stated from Shennong's Herbal, classifies as top grade.After this how on the books book on Chinese herbal medicine is the successive dynasties, but kind differs, and successively relates to ten several plants of a plurality of sections.Wherein mainly contain the Radix Dipsaci of Dipsacaceae, the Herba phlomidis of Labiatae, the Ji of Compositae etc., but begin from the Ming Dynasty, the Radix Dipsaci of Dipsacaceae just becomes the main flow of medicinal Radix Dipsaci, has arrived the Qing Dynasty, and Radix Dipsaci just becomes unique certified products source of Radix Dipsaci and continues into the present.The modern chemistry result of study shows that Radix Dipsaci contains glycoside, aminoacid, phenols, Saponin, alkaloid etc.Pharmaceutical research shows that Radix Dipsaci can significantly increase the content of rat blood serum calcium, phosphorus, 25-hydroxyl VD, and improves the density of X-light sclerotin picture.The Radix Dipsaci ethanol extraction has facilitation to the rat test bone injury healing, and the amount effect relationship.
Radix Notoginseng is an Araliaceae Panax herbaceos perennial, the Compendium of Material Medica record: " it is little sweet and bitter to distinguish the flavor of, quite seemingly the flavor of Radix Ginseng." " all canes are pounced on trauma, and the dripping person of blood stasis chews promptly ending of mashed net for catching birds or fish immediately, and bruise the person promptly dissipate.If when being subjected to cane, clothes one, two money earlier, then the blood centre of punch not should be obeyed it behind the cane especially, and obey also good puerperal.On the whole this medicine temperature, sweet and slightly bitter taste, and sun is bright, the medicine of the cloudy blood system of fainting, so can control all disorders of blood ".Modern pharmacology is studied surperficial Radix Notoginseng in the treatment cardiovascular disease, and regulating new one-tenth metabolism aspect has apparent in view pharmacological action, and the main effective ingredient of Radix Notoginseng is an arasaponin, and it has the effect of significant calmness and physical strength reinforcing the pharmacological evaluation surface.
Flos Carthami is a gas medicine in the blood.Theory of Chinese medical science is thought: chest arthralgia precordial pain syndrome belongs to the deficiency in origin and excess in superficiality card more, and the treatment of chest arthralgia precordial pain syndrome pain phase is many to take stopgap measures based on relieving pain and activating blood circulation, the silt QI regulating medicine of dispelling; After the pain relief then based on regulating YIN and YANG internal organs QI and blood.So Flos Carthami can be used for these deficiency syndrome person, can invigorate blood circulation again, loose become silted up and pain relieving, with the excess syndrome person of taking stopgap measures.
The medicine of treatment orthopaedic disease normally contains estrogenic chemicals in the modern medicine, and drug side effect is big during clinical use, and Chinese medicine is because of its special effect and the little favor of firmly getting doctor and patient of side effect.Chinese medicine prescription before the retrieval finds that Herba Epimedii and Radix Dipsaci are extensive use of in the prescription of treatment orthopaedic disease.Studies have shown that through us, although Herba Epimedii extract and Radix Dipsaci extract itself use separately just has the effect that prevents and treat orthopaedic disease, but the compositions that pharmacology and clinical trial show Herba Epimedii extract and Radix Dipsaci extract has the effect of stronger prevention and treatment orthopaedic disease during than their independent uses, synergism between them effectively raises drug effect, and the pharmacology performance is more obvious.Pharmacological action is suitable after adding Radix Notoginseng extract or Flos Carthami extract on the basis of this drug regimen.Needs for current clinical medicine, we make modern capsule, injection type and freezing-dried powder injection type with this pharmaceutical composition at research, and drug effect is definite, and is rapid-action, clinical easy to use, for clinical prevention and treatment orthopaedic disease provide a kind of new effective drug regimen.
Summary of the invention
Through us a large amount of scientific researches and clinical trial, the drug regimen of having found Herba Epimedii and Radix Dipsaci extract has the effect of very strong prevention and treatment orthopaedic disease, and this invention has been done further perfect, this compositions made be convenient to the pharmaceutical preparation that clinical implementation is used.
An object of the present invention is to provide and a kind ofly can effectively prevent and treat the Herba Epimedii of orthopaedic disease and the pharmaceutical composition of Radix Dipsaci extract, it is more more effective than each component more than using separately to prove its effect through pharmacology and clinical trial.Test finds, add Radix Notoginseng extract or Flos Carthami extract in this pharmaceutical composition after pharmacological tests suitable.
Another object of the present invention provides a kind of production technology for preparing above compositions.
Take by weighing Herba Epimedii 5kg, add 70% ethanol extraction 3 times of 10 times of amounts, each 1.5 hours, reclaim ethanol, water-bath concentrates, and evaporate to dryness gets Herba Epimedii extract.
Take by weighing Radix Dipsaci 5kg, add 70% ethanol extraction 3 times of 10 times of amounts, each 1.5 hours, reclaim ethanol, water-bath concentrates, macroporous adsorbent resin D-101 post on the solution, with 3BV (Bed Volume, bed volume) Liang water washing post bed, 70% ethanol elution of reuse 2BV amount, merging filtrate and cleaning mixture, filtrate recycling ethanol, 80 ℃ of drying under reduced pressure 8 hours are pulverized, Radix Dipsaci extract.
Get pseudo-ginseng, 60 ℃ of dryings 8 hours are ground into coarse powder (24 order), take by weighing 1 kilogram of coarse powder, and dipping spends the night, and with the flow velocity percolation of 10 times of 75% ethanol with 1-3ml/min.kg, percolate reclaims ethanol, drying under reduced pressure, crude product.Crude product adds 15 times of water dissolutioies, macroporous adsorbent resin D-101 post on the solution, with the water washing post bed of 3BV (Bed Volume, bed volume) amount, 70% ethanol elution of reuse 2BV amount, eluent adds 1 kilogram of neutral alumina, reflux 15 minutes filters, and filtering residue is with an amount of 70% washing with alcohol 2 times, merging filtrate and cleaning mixture, add activated carbon 20g again, refluxed 30 minutes, filter, filtering residue is with an amount of 70% washing with alcohol 2 times, merging filtrate and cleaning mixture, filtrate recycling ethanol, 80 ℃ of drying under reduced pressure 8 hours, pulverize, get Radix Notoginseng extract.
The prescription of pharmaceutical composition of the present invention is as follows:
Herba Epimedii extract: 1-99 weight ratio Radix Dipsaci extract: 1-99 weight ratio
Adopt the preparation technique in existing medical industry field, the pharmaceutical composition of above-mentioned prescription can be made the various pharmaceutical dosage forms that are fit to clinical use.
Following content is the pharmacology test result of checking pharmaceutical composition of the present invention:
(1) this product is to the influence of experimental osteoporosis
Experimental animal: 60 of Wistar rats, female, 16 ages in week, body weight 220 ~ 240g.
Experimental apparatus: dual intensity X line bone density detection limit instrument: U.S. Nodand company produces, instrument model: XR226.
Experimental technique
Rat experiment osteoporosis experiment: each organizes the rat sub-cage rearing in the stainless steel metal cage, 5 in every cage, and room temperature is adjusted in 22-26 ℃, and humidity is controlled at 50% ~ 70%, free diet and take the photograph water.Animal is weighed, and adopts the stratified random method that 60 of rats are divided into 6 groups, i.e. the blank group: 0.9% sodium chloride injection (10ml/kg); Model control group: 0.9% sodium chloride injection (10ml/kg); This product: heavy dose of group (800mg/Kg); This product: middle dosage group (400mg/Kg); This product: small dose group (200mg/Kg); Treatment medicine for treating osteoporosis matched group: GUSONGBAO KELIJI (2.7g/Kg).
Weigh once for every group in the experimentation, regulate dosage according to rat body weight.Blank group is only given the equivalent normal saline in whole experiment, model group, GUSONGBAO KELIJI group, each dosage group of this product capsule all gave retinoic acid (70mgg on the 1st ~ 15 day in experiment
-1Dd
-1) the filling stomach, the GUSONGBAO KELI group adds GUSONGBAO KELI simultaneously, and this product group adds each corresponding dosage of this product, the inactive retinoic acid of each group behind the 14d, blank group, model group award the equivalent normal saline, the administration group continues to give institute's reagent thing, and dosage is constant, the 29th day, anesthetized animal and abdominal aortic blood, separation of serum is measured blood calcium, serium inorganic phosphorus with full automatic biochemical apparatus, puts to death animal, has separated complete femur, the 2nd ~ 4 lumbar vertebra in both sides and has carried out the detection of bone density.
Result of the test:
Table 1: the influence that this product capsule changes rat bone density (x ± s, n=10)
| Group | Dosage | Femoral bmd (gcm -2) | Lumbar spine bmd (gcm -2) |
| Dosage group this product low dose group in blank group model matched group GUSONGBAO group this product high dose group this product | 10ml/kg - 2.7g/kg 800mg/kg 400mg/kg 200mg/kg | 0.149±0.091** 0.098±0.052 0.127±0.099** 0.145±0.102** 0.139±0.057** 0.126±0.089* | 0.158±0.033** 0.101±0.020 0.128±0.036** 0.152±0.039** 0.145±.038** 0.127±0.059* |
Annotate: compare * P＜0.05 with model control group; * P＜0.01
This product is to the influence of rat bone density: the bone density that the high, medium and low dosage group of this product causes the experimental rat osteoporosis reduces obvious inhibitory action, can the raise effect (P＜0.05 ~ 0.001) of rat femur and lumbar spine bmd, GUSONGBAO also has the effect (P＜0.05) of rising rat femur and lumbar spine bmd.
Table 2 this product capsule to the influence of rat blood calcium, serium inorganic phosphorus (x ± s, n=10)
| Group | Dosage | Blood calcium (mgL -1) | Serium inorganic phosphorus (mgL -1) |
| Dosage group this product low dose group in blank group model matched group GUSONGBAO group this product high dose group this product | 10mL/Kg - 2.7g/Kg 800mg/Kg 400mg/Kg 200mg/Kg | 126.4±8.5** 97.9±5.14 108.5±4.63* 124.9±8.24** 118.3±6.51* 106.5±4.29 | 52.34±6.33** 37.66±4.57 43.12±5.28* 49.37±4.65** 45.64±5.04* 42.25±6.43 |
This product is to the influence of rat blood calcium, serium inorganic phosphorus: three dosage groups of this product cause the calcium level of Osteoporosis Rats that significant rising effect is arranged to retinoic acid, relatively there were significant differences (P＜0.05) with model group, and GUSONGBAO also has the effect (P＜0.05) of rising rat blood calcium, serium inorganic phosphorus.This product does not have obvious effect to the rat serium inorganic phosphorus.
(2) analgesic activity:
2.1 causing, mice chemical stimulation method intends pain reaction (writhing method) experiment
60 of one-level ICR mices, body weight 18～22g is divided into 5 groups at random, and 12 every group, male and female half and half, grouping and administration situation see Table 3.
Table 3 Dichlorodiphenyl Acetate causes the influence test administration and the grouping situation of mouse writhing reaction
| Group | Number of animals | Dosage (mg/kg) | Dosage (ml/kg) | Quite clinical multiple |
| Dosage group low dose group in the blank positive control high dose group | 12 12 12 12 12 | Distilled water pethidine 33mg/kg 800 400 200 | i.g.20 i.p.10 i.g.20 i.g.20 i.g.20 | - 10 20 10 5 |
Each treated animal removes the positive and organizes 15min disposable celiac drug administration by injection before injection acetic acid by last table administration, and other respectively organizes administration every day 1 time, continuous 7 days, 45min after the last administration, each Mus lumbar injection 0.6% acetic acid 0.2ml/ only observe each animal writhing response number of times in the 15min.Calculate medicine analgesia percentage rate.
The results are shown in Table 4
Table 4 Dichlorodiphenyl Acetate causes the influence of mouse writhing reaction
| Group | Number of animals | Dosage (mg/kg) | Turn round body number of times (x ± s) | Analgesia rate (%) |
| Blank positive control high dose group | 12 12 12 | Distilled water pethidine 33mg/kg 800 | 36.47±8.41 9.55±6.84*** 15.62±9.15*** | - 73.81 57.17 |
| Middle dosage group low dose group | 12 12 | 400 200 | 20.69±10.21** 25.94±6.78 | 43.27 28.87 |
Annotate: compare * * * p＜0.001 with the blank group; * p＜0.01.
Table 4 is the result show, this specialty product Dichlorodiphenyl Acetate causes the mouse writhing reaction and has obvious inhibitory action, compare with the blank group, and high dose group p＜0.001, middle dosage group p＜0.01, prompting this product Dichlorodiphenyl Acetate causes pain and has obvious analgesic effect.
2.2 conduction of heat causes mice plan pain reaction (hot plate method) experiment
One-level ICR mice, body weight 18～22g, female; RB-200 intelligence hot-plate instrument, 55 ± 0.5 ℃ of program control temperatures, lick metapedes for causing the pain index with mice, the used time is its pain threshold when occurring licking metapedes, measure the normal pain threshold of each Mus, 50 of the normal mice of pain threshold between 5～30s in choosing pool are divided into 5 groups at random, every group 10, grouping and administration situation see Table 5.
Table 5 pair mice hot plate causes the influence test administration and the grouping situation of pain
| Group | Number of animals | Dosage (mg/kg) | Dosage (ml/kg) | Quite clinical multiple |
| Dosage group low dose group in the blank positive control high dose group | 10 10 10 10 10 | Distilled water pethidine 33mg/kg 800 400 200 | i.g.20 i.p.10 i.g.20 i.g.20 i.g.20 | - 10 20 10 5 |
After measuring normal pain threshold, each treated animal is by last table administration, after the administration 30,60,90min (pethidine group be 15,60,90min) measures pain threshold after each Mus administration respectively, calculates the threshold of pain and improves percentage rate.
Statistical procedures: adopt SPSS10.0 software one factor analysis of variance to add up, data result is added and subtracted standard deviation (x ± s) expression with mean.
The results are shown in Table 6.
Table 6 pair mice hot plate causes the influence of pain
| Group | Number of animals | Threshold of pain raising percentage rate (x ± s) | ||
| 30min | 60min | 90min | ||
| Blank positive control high dose group | 10 10 10 | 0.02±0.11 1.85±0.98*** 1.32±0.52 | 0.05±0.37 1.62±0.34** 1..16±0.49** | 0.06±0.31 1.05±0.33 1.08±0.45* |
| Middle dosage group low dose group | 10 10 | 0.61±0.44 0.38±0.62 | 0.52±0.43** 0.29±0.36** | 0.47±0.36* 0.24±0.54 |
Compare * * * p＜0.001 with the blank group; * p＜0.01; * p＜0.05.
Table 6 is the result show, this product can obviously improve the pain threshold that hot plate causes the pain mice, compares senior middle school's low dose group p＜0.01 during 60min, height, middle dosage group p＜0.05 during 90min with the blank group.Prompting this product causes the pain mice to hot plate tangible analgesic effect.
(3): this product capsule anti-inflammatory experimentation
3.1 xylol causes the influence of mice auricle swelling
60 of male ICR mouses are divided into model control group, positive controls at random by body weight, the high, medium and low dosage group of this product capsule, totally 5 groups, 12 every group.Senior middle school low dose group rat is irritated stomach respectively and gives this product 800,400,200mg/kg, positive controls is irritated stomach and is given dexamethasone acetate tablets 1.0mg/kg, model group gives the equal-volume normal saline, every day 1 time, continuous 7 days, after the last administration 1 hour, 50 μ l dimethylbenzene are applied to two sides before and after every mouse right ear.Taking off neck after 4 hours and put to death, cut ears, is that 8mm rustless steel punching pin sweeps away left and right sides auricle with diameter, weigh, as the index of weighing the swelling degree, antiinflammatory action intensity is carried out statistical analysis with suppression ratio (%) expression with the SPSS11.5 software kit with the difference of two auricle weight.The results are shown in Table 7.
The influence of table 7 pair mice ear (x ± s)
| Group | Number of animals (only) | Swelling degree (mg) | Suppression ratio (%) |
| Dosage group low dose group in the model control group positive controls high dose group | 12 12 12 12 12 | 16.54±3.05 3.95±1.26*** 4.06±2.18** 8.56±2.15* 9.66±3.52* | -- 76.12 75.45 48.25 41.60 |
Compare with model control group: * p＜0.05, * * p＜0.01, * * * p＜0.001
Experimental result shows that this product capsule xylol causes mice auricle swelling obvious inhibitory action, and its high dose group and model group relatively have utmost point significant difference.
3.2 inhibitory action to the rising of mouse peritoneal capillary permeability
60 of male ICR mouses are divided into model control group, positive controls at random by body weight, the high, medium and low dosage group of this product capsule, totally 5 groups, 12 every group.Senior middle school low dose group rat is irritated stomach respectively and gives this product 800,400,200mg/kg, positive controls is irritated stomach and is given dexamethasone acetate tablets 1.0mg/kg, model group gives the equal-volume normal saline, every day 1 time, continuous 7 days, 30min after the last administration, tail vein injection 0.5% azovan blue solution 0.1ml/10g body weight, lumbar injection 0.6% glacial acetic acid solution 0.2ml/ is only immediately.Behind the 20min, cut off abdominal cavity skin,, on 751 type spectrophotometers, measure its light absorption value with 5ml normal saline flushing abdominal cavity, the whole abdominal cavities of sucking-off washing liquid.With its abdominal cavity capillary permeability situation of OD value reflection.The results are shown in Table 8.
The influence that table 8 pair mouse peritoneal capillary permeability increases (x ± s)
| Group | Number of animals (only) | The OD value |
| Dosage group low dose group positive controls in the model control group high dose group | 12 12 12 12 12 | 0.566±0.2.54 0.184±0.135* 0.246±0.323 0.371±0.412 0.410±0.258** |
Compare with model control group: * p＜0.05, * * p＜0.01.
Annotate: number of animals is for injecting successfully, include in the number of mice of statistical analysis in the table.
Last table result shows that this product capsule Dichlorodiphenyl Acetate causes the increase of mouse peritoneal capillary permeability and has the obvious suppression effect, and relatively there were significant differences for high dose group and model control group.
Specific embodiment
Below in conjunction with the specific embodiment to the further detailed description that the present invention did, the present invention is not imposed any restrictions:
Embodiment 1: capsule prescription and technology
Prescription (by 1000)
Herba Epimedii extract 20g
Radix Dipsaci extract 20g
Starch 150ml
Micropowder silica gel 10g
Make 1000
Take by weighing Herba Epimedii 5kg, add 70% ethanol extraction 3 times of 10 times of amounts, each 1.5 hours, reclaim ethanol, water-bath concentrates, and evaporate to dryness gets Herba Epimedii extract.
Take by weighing Radix Dipsaci 5kg, add 70% ethanol extraction 3 times of 10 times of amounts, each 1.5 hours, reclaim ethanol, water-bath concentrates, macroporous adsorbent resin D-101 post on the solution, with 3BV (Bed Volume, bed volume) Liang water washing post bed, 70% ethanol elution of reuse 2BV amount, merging filtrate and cleaning mixture, filtrate recycling ethanol, 80 ℃ of drying under reduced pressure 8 hours are pulverized, Radix Dipsaci extract.
Embodiment 2: powder pin prescription and technology
Prescription (by 1000 bottles)
Herba Epimedii extract 100g
Radix Dipsaci extract 100g
Mannitol 250ml
Water for injection 10g
Make 1000 bottles
Extracting method is the same.Moulding process is: get recipe quantity Herba Epimedii extract, Radix Dipsaci extract, Radix Notoginseng extract, mannitol, PEG400, the dissolving of 80% recipe quantity water for injection; Just filter back reuse 0.2um microporous filter membrane fine straining; Supply water for injection to full dose; Packing; Lyophilizing; Packing.
Example 3: injection formula and technology
Prescription (by 1000 bottles)
Herba Epimedii extract 100g
Radix Dipsaci extract 100g
Water for injection adds to 2000ml
Make 1000 bottles
Extracting method is the same.Moulding process is: get recipe quantity Herba Epimedii extract, Radix Dipsaci extract, Radix Notoginseng extract, the dissolving of 50% recipe quantity water for injection; Active carbon is just filtered back reuse 0.2um microporous filter membrane fine straining; Supply water for injection to full dose; Measure content; Packing; Sterilization; Lamp inspection; Packing.
Example 4: tablet formulation and technology
Prescription (by 1000)
Herba Epimedii extract 20g
Radix Dipsaci extract 20g
Starch 150g
Hydroxypropyl cellulose 7g
Sodium Hydroxymethyl Stalcs 7g
Micropowder silica gel 10g
Make 1000
Extracting method is the same.Moulding process is: get recipe quantity Herba Epimedii extract, Radix Dipsaci extract, Radix Notoginseng extract, starch, carboxymethyl starch sodium is made adhesive with 5% hydroxypropyl cellulose, the system soft material, and 20 mesh sieves are granulated, and 60 ℃ of dryings add the micropowder silica gel granulate, tabletting.
Example 5: pill prescription and technology
Prescription (by 1000)
Herba Epimedii extract 20g
Radix Dipsaci extract 20g
Polyethylene glycol 6000 200g
Make 1000
Extracting method is the same.Moulding process is: taking polyethylene glycol 6000 is heated to 90-100 ℃ in oil bath, after treating all dissolvings, add Herba Epimedii extract, Radix Dipsaci extract, Radix Notoginseng extract, be stirred to dissolving, be transferred in the reservoir, airtight and be incubated again 80-90 ℃, regulate the dropping liquid quantitative valve, splash in 10-15 ℃ the liquid paraffin, the drop pill that forms is drained and the erasing liquor paraffin body drying.
Claims (13)
1, the pharmaceutical composition of a kind of prevention and treatment orthopaedic disease is characterized in that the prescription of this pharmaceutical composition is: Herba Epimedii 1-99 weight ratio, Radix Dipsaci extract 1-99 weight ratio.
2, the pharmaceutical composition of a kind of prevention and treatment orthopaedic disease is characterized in that the prescription of this pharmaceutical composition is: Herba Epimedii 35-60 weight ratio, Radix Dipsaci extract 40-65 weight ratio.
3, according to the pharmaceutical composition of described prevention of claim 1 and treatment orthopaedic disease, it is characterized in that Herba Epimedii extract can replace with the Herba Epimedii crude drug, Radix Dipsaci extract can replace with the Radix Dipsaci crude drug.
4, according to the pharmaceutical composition of described prevention of claim 1 and treatment orthopaedic disease, it is characterized in that this pharmaceutical composition can also add the Radix Notoginseng extract of 0-98 weight ratio.
5,, it is characterized in that Radix Notoginseng extract can replace with the Radix Notoginseng crude drug according to the pharmaceutical composition of described prevention of claim 4 and treatment orthopaedic disease.
6, according to the pharmaceutical composition of described prevention of claim 1 and treatment orthopaedic disease, it is characterized in that this pharmaceutical composition can also add the Flos Carthami extract of 0-98 weight ratio.
7,, it is characterized in that Flos Carthami extract can replace with the Flos Carthami crude drug according to the pharmaceutical composition of described prevention of claim 6 and treatment orthopaedic disease.
8, according to the pharmaceutical composition of described prevention of claim 1 and treatment orthopaedic disease, it is characterized in that the Herba Epimedii total flavones weight ratio is 10-100 in the Herba Epimedii extract, the dipsacoside weight ratio is 10-100 in the Radix Dipsaci extract.
9, according to the pharmaceutical composition of described prevention of claim 4 and treatment orthopaedic disease, it is characterized in that the arasaponin weight ratio is 10-100 in the Radix Notoginseng extract.
10, according to the pharmaceutical composition of described prevention of claim 6 and treatment orthopaedic disease, it is characterized in that the Flos Carthami total flavone weight ratio is 10-100 in the Flos Carthami extract.
11,, it is characterized in that it is applicable to treatment osteoporosis, joint disease, hyperosteogeny, orthopaedic diseases such as osteomyelitis and bones and tendons injury pain clinically according to the pharmaceutical composition of described prevention of claim 1 and treatment orthopaedic disease.
12, according to the described prevention of claim 1 and treatment osteoporosis and antiphlogistic pharmaceutical composition, it is characterized in that: its dosage form is any pharmaceutical dosage form in the acceptable dosage form on the pharmaceuticss such as the injection (comprising transfusion, freeze-dried powder) that is fit to clinical practice, pill, drop pill, tablet (comprising dispersible tablet, oral cavity disintegration tablet etc.), slow releasing tablet, capsule, soft capsule, granule, powder, lozenge, soft extract, oral liquid (mixture), syrup, ointment, liniment, liniment.
13, the preparation of drug combination method of a kind of prevention and treatment orthopaedic disease is characterized in that it may further comprise the steps:
(1) take by weighing Herba Epimedii 5kg, add 70% ethanol extraction 3 times of 10 times of amounts, each 1.5 hours, reclaim ethanol, water-bath concentrates, and evaporate to dryness gets Herba Epimedii extract;
(2) take by weighing Radix Dipsaci 5kg, add 70% ethanol extraction 3 times of 10 times of amounts, each 1.5 hours, reclaim ethanol, water-bath concentrates, macroporous adsorbent resin D-101 post on the solution, with 3BV (Bed Volume, bed volume) Liang water washing post bed, 70% ethanol elution of reuse 2BV amount, merging filtrate and cleaning mixture, filtrate recycling ethanol, 80 ℃ of drying under reduced pressure 8 hours are pulverized, Radix Dipsaci extract;
(3) get 100g Herba Epimedii extract, 100g Radix Dipsaci extract, the dissolving of 50% recipe quantity water for injection; Active carbon is just filtered back reuse 0.2um microporous filter membrane fine straining; Supply water for injection to full dose; Measure content; Packing; Sterilization; Lamp inspection; Packing is made 1000 bottles of Chinese medicines of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510088791 CN1907315A (en) | 2005-08-02 | 2005-08-02 | Orthopaedics disease treating and preventing medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510088791 CN1907315A (en) | 2005-08-02 | 2005-08-02 | Orthopaedics disease treating and preventing medicinal composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1907315A true CN1907315A (en) | 2007-02-07 |
Family
ID=37698652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510088791 Pending CN1907315A (en) | 2005-08-02 | 2005-08-02 | Orthopaedics disease treating and preventing medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1907315A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780132B (en) * | 2009-01-17 | 2012-03-07 | 毕力夫 | Mongolian medicine for treating osteoporosis and preparation method thereof |
| CN105770058A (en) * | 2016-04-11 | 2016-07-20 | 山东省文登整骨医院 | Traditional Chinese medicine composition for treating orthopedic diseases and preparation method and application thereof |
-
2005
- 2005-08-02 CN CN 200510088791 patent/CN1907315A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101780132B (en) * | 2009-01-17 | 2012-03-07 | 毕力夫 | Mongolian medicine for treating osteoporosis and preparation method thereof |
| CN105770058A (en) * | 2016-04-11 | 2016-07-20 | 山东省文登整骨医院 | Traditional Chinese medicine composition for treating orthopedic diseases and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1245187C (en) | Medicine for treating eye disease caused by visceral disease | |
| CN1907316A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN104784505A (en) | Dendrobium officinale healthcare product with auxiliary blood glucose reducing function and preparation method thereof | |
| CN1742775A (en) | Medicine composition for preventing and treating orthopedic diseases | |
| CN101007157A (en) | Traditional Chinese medicine compound preparation for treating chronic cholecystitis | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1256120C (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1907315A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN1182864C (en) | Medicine for vascular denmentia disease and preparation method | |
| CN104474103A (en) | Natural plant hypoglycemic agent and preparation method thereof | |
| CN1814163A (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN1899439A (en) | Chinese medicine composition for treating goat and its use | |
| CN104922488B (en) | A kind of Chinese medicine composition for preventing and treating Parkinson's or Parkinson's motor complication and its preparation method and application | |
| CN104223062B (en) | Root bark of Chinese wolf-berry health care oral liquid of a kind of reducing pressure and sugar and preparation method thereof | |
| CN103623109A (en) | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN105920189A (en) | Traditional Chinese medicine composition for treating talalgia due to liver-kidney deficiency and preparation method thereof | |
| CN1313126C (en) | Medicine composition for treating hyperlipemia and its preparing method | |
| CN105998532A (en) | Preparation method for traditional Chinese medicine for treating Qi-stagnancy and blood stasis painful heel and composition of traditional Chinese medicine | |
| CN1446554A (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1679742A (en) | Medicine for treating dysmenorrhes and preparation thereof | |
| CN1824075A (en) | Medicinal composition for treating hemicrania and its application | |
| CN1304043C (en) | Longhedan pills and their preparation | |
| CN1216634C (en) | Medicinal composition for treating pain | |
| CN1907424A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN103157040A (en) | Pharmaceutical composition for treating multiple osteoenchondroma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Sun Yi Document name: Notice of publication of application for patent for invention |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20070207 |